A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.

Abstract	The FDA has approved incobotulinumtoxinA (Xeomin--Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.
Authors
Journal	The Medical letter on drugs and therapeutics (Med Lett Drugs Ther) Vol. 52 Issue 1351 Pg. 90-1 (Nov 15 2010) ISSN: 1523-2859 [Electronic] United States
PMID	21068703 (Publication Type: Journal Article, Review)
Chemical References	Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA
Topics	Animals Blepharospasm (drug therapy, physiopathology) Botulinum Toxins (adverse effects, therapeutic use) Botulinum Toxins, Type A Chemistry, Pharmaceutical Humans Muscle Weakness (chemically induced) Randomized Controlled Trials as Topic (methods) Torticollis (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!